注意欠陥・多動性障害（ADHD）の小児におけるチペピジン：二重盲検プラセボ対照試験

基本情報

NCT ID: NCT02305134
ステータス: 完了
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 21
治験依頼者名: Chiba University

概要

Tipepidine (3-\[di-2-thienylmethylene\]-1-methylpiperidine) has been used solely as a nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults has already been established. It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by tipepidine is expected to modulate the level of monoamines in the brain. We put forward the hypothesis that tipepidine can improve attention deficit/hyperactivity disorder (ADHD) symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK channels. The purpose of this double-blind, placebo-controlled trial is to confirm whether treatment with tipepidine can improve symptoms in pediatric patients with ADHD.

対象疾患

Attention Deficit Disorder With Hyperactivity DiseaseHyperkinesisAttention Deficit and Disruptive Behavior Disorders

介入

Tipepidine Hibenzate(DRUG)

Placebo(DRUG)

依頼者（Sponsor）

Chiba University(OTHER)

実施施設 (1)

千葉大学医学部附属病院

Chiba, Chuo-ku, Japan